Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Imunon ( (IMNN) ) is now available.
On May 22, 2025, Imunon, Inc. requested the withdrawal of its Registration Statement No. 333-286403 from the Securities and Exchange Commission, deciding not to pursue the associated public offering. The withdrawal is expected to be effective as of May 22, 2025, unless the Commission objects within 15 days, impacting the company’s financial strategy and market approach.
The most recent analyst rating on (IMNN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Imunon stock, see the IMNN Stock Forecast page.
Spark’s Take on IMNN Stock
According to Spark, TipRanks’ AI Analyst, IMNN is a Neutral.
Imunon’s financial instability, characterized by negative revenue and cash flow metrics, significantly impacts its overall stock score. Technical indicators suggest caution, with bearish trends and lack of momentum. Though the recent earnings call highlights promising clinical progress, concerns about cash runway and funding remain. Valuation metrics further reflect the stock’s risky profile, with a negative P/E ratio and no dividend yield.
To see Spark’s full report on IMNN stock, click here.
More about Imunon
Average Trading Volume: 219,269
Technical Sentiment Signal: Sell
Current Market Cap: $7.76M
For a thorough assessment of IMNN stock, go to TipRanks’ Stock Analysis page.